Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Robert E. Sobol"'
Autor:
Robert E. Sobol, Kerstin B. Menander, Sunil Chada, Dora Wiederhold, Beatha Sellman, Max Talbott, John J. Nemunaitis
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundWe conducted an analysis of previous adenoviral p53 (Ad-p53) treatment data in recurrent head and neck squamous cell carcinoma (HNSCC) patients to identify optimal Ad-p53 treatment methods for future clinical trials.MethodsThe analysis invo
Externí odkaz:
https://doaj.org/article/e071119b1cfd4ac88efdb2e379e13fd4
Autor:
Robert E. Sobol, Kerstin B. Menander, Dora Wiederhold, Sunil Chada, Beatha Sellman, Chae-Ok Yun, John Nemunaitis, Hyo Min Ahn, Bo-Kyeong Jung, Max Talbott
Publikováno v:
Cancer Gene Therapy. 29:825-834
Background While immune checkpoint inhibitors are becoming a standard of care for multiple types of cancer, the majority of patients do not respond to this form of immunotherapy. New approaches are required to overcome resistance to immunotherapies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fa7aa4c27ce026bc65fc2fd996f50a6
https://doi.org/10.1038/s41417-021-00369-7
https://doi.org/10.1038/s41417-021-00369-7
Autor:
Sunil Chada, Robert E. Sobol, Dora Wiederhold, Beatha Sellman, Kerstin B. Menander, Max Talbott, John Nemunaitis
BackgroundWe conducted a meta-analysis of previous adenoviral p53 (Ad-p53) treatment data in recurrent head and neck squamous cell carcinoma (HNSCC) patients to identify optimal Ad-p53 treatment methods for future clinical trials.MethodsThe meta-anal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fc0573701560a2e8be0e8540f77acd6
https://doi.org/10.1101/2021.01.06.20248743
https://doi.org/10.1101/2021.01.06.20248743
Autor:
Chae-Ok Yun, Dora Wiederhold, Robert E. Sobol, Kerstin B. Menander, Hyomin Ahn, Sunil Chada, Eonju Oh
Publikováno v:
Journal of Clinical Oncology. 36:64-64
64 Background: Immune checkpoint inhibitors represent an important advance in cancer therapeutics. However, most cancer patients either do not respond or become resistant to this therapy. Methods: We evaluated the ability of tumor suppressors p53 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20e32c7721134ae748aa311c2d19bb47
https://doi.org/10.1200/jco.2018.36.5_suppl.64
https://doi.org/10.1200/jco.2018.36.5_suppl.64
Autor:
Louis A. Zumstein, Rosalind A. Eeles, Kerstin B. Menander, Frank J. Lynch, Hani Gabra, John Nemunaitis, Robert E. Sobol, Jeffrey P. Lamont, Nayanta Sodha, Sunil Chada, Martin Gore, Neil Senzer, Michael Nemunaitis
Publikováno v:
Molecular Cancer Therapeutics. 6:1478-1482
Li-Fraumeni syndrome is an autosomal dominant disorder that greatly increases the risk of developing multiple types of cancer. The majority of Li-Fraumeni syndrome families contain germ-line mutations in the p53 tumor suppressor gene. We describe tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ea26a05942951bac5278ed2f12c857a
https://doi.org/10.1158/1535-7163.mct-07-0125
https://doi.org/10.1158/1535-7163.mct-07-0125
This book is a collection of preclinical and clinical reports on the application of gene therapy to human disease. The two methods available for delivering therapeutic genes to diseased cells, viral and non-viral vector systems, are detailed and char
Autor:
Kerstin B. Menander, Ravi Murthy, Robert E. Sobol, Vivek Subbiah, Dora Wiederhold, Chae-Ok Yun, Sunil Chada, Hyomin Ahn, Eonju Oh
Publikováno v:
Journal of Clinical Oncology. 35:e14610-e14610
e14610 Background: Immune checkpoint inhibitors represent an important advance in cancer therapeutics. However, most cancer patients do not respond or become resistant to this form of immune therapy. Methods: We evaluated the ability of Ad-p53 to rev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2eabc61269e0bc55cc72741bdfc7df3
https://doi.org/10.1200/jco.2017.35.15_suppl.e14610
https://doi.org/10.1200/jco.2017.35.15_suppl.e14610
Autor:
Habib Fakhrai, Daniel L. Shawler, Jonathan S. Berek, Robert E. Sobol, Oliver Dorigo, Ivor Royston
Publikováno v:
Gynecologic Oncology. 71:204-210
The immunosuppressive protein transforming growth factor beta (TGF-beta) inhibits the activation of various immune effector cells including cytotoxic T lymphocytes and may therefore inhibit the efficacy of immunostimulatory interleukin-2 (IL-2) gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b168a053a8723a7a5e149f52ed15046c
https://doi.org/10.1006/gyno.1998.5151
https://doi.org/10.1006/gyno.1998.5151
Autor:
Dan Mercola, Jason J. Scalise, Robert E. Sobol, Ruth A. Gjerset, Penelope J. Hopkins, Heli Collins, Sally T. Turla
Publikováno v:
Molecular Carcinogenesis. 14:275-285
It is known that transfer of the wild-type p53 gene into p53-negative cells from transgenic mice increases their sensitivity to drug and radiation-induced apoptosis. However, unlike many human tumors, these transgenic cells do not express mutant p53,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8adeab1ac76b4708a0091e2610e969fd
https://doi.org/10.1002/mc.2940140408
https://doi.org/10.1002/mc.2940140408
Autor:
James A. Koziol, Robert E. Sobol, Daniel L. Shawler, Ruth A. Gjerset, Habib Fakhrai, Robert K. Naviaux, Ivor Royston
Publikováno v:
Human Gene Therapy. 6:591-601
We evaluated the effects of different doses of interleukin-2 (IL-2)-transduced fibroblasts in the treatment of colorectal carcinoma in the CT-26 murine tumor model. Immunization with a mixture of irradiated tumor cells and IL-2-transduced fibroblasts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5be3573ec8c56f5340463b5a1e92fdd5
https://doi.org/10.1089/hum.1995.6.5-591
https://doi.org/10.1089/hum.1995.6.5-591